Editor’s Note: Related tickers: Amarin Corporation plc (ADR) (NASDAQ:AMRN)
Amarin Co. plc Receives “Outperform” Rating from Leerink Swann (AMRN) (UtahPeoplesPost)
Leerink Swann reissued their outperform rating on shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) in a research report released on Thursday morning, Stock Ratings Network reports. Amarin Corporation plc (ADR) (NASDAQ:AMRN) traded up 4.14% on Thursday, hitting $7.55. Amarin Co. plc has a 52-week low of $6.55 and a 52-week high of $15.96. The stock’s 50-day moving average is currently $7.62. The company’s market cap is $1.136 billion. …Amarin Corporation plc (ADR) (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Quarterly sends Amarin stock soaring (TheDay)
Dublin-based biotech Amarin Corporation plc (ADR) (NASDAQ:AMRN) plc’s stock took a ride upward Friday, one day after releasing first-quarter financial results that gave an early glimpse of how sales of its newly approved heart medication, Vascepa, are proceeding. Amarin, which has research-and-development headquarters in Groton, said it has seen a near-quadrupling of Vascepa prescriptions since its first full month of sales in February. The company added that more than 4,000 clinicians nationwide have prescribed Vascepa at least once. The sales trajectory boosted Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s stock price Friday as it ticked up by more than 6 percent. The price closed on the Nasdaq exchange at $7.25, up 42 cents.
Amarin Reports Solid Vascepa TRx Growth, Stock Holds It’s Ground (ProActiveInvestors)
Last week was quite decent for Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors, who saw a 6% rally last Friday in reaction to the company’s Q1 2013 financial results. Of particular interest was the continued growth in Vascepa (icosapent ethyl) capsules, which were approved for hypertriglyceridemia patients with 500+ mg/dL concentration in mid-2012. The launch at the end of January 2013 went surprisingly well, although it seems that Wall Street is still underwhelmed by the numbers that have been posted up to this point. In the first quarter of 2012 (or the quarter ended March 31st, 2013) Amarin reported $2.34 million in product revenues, although the company mentioned $2.9 million of deferred product revenue that will contribute to revenues in Q2 2012 results which are due in August 2013.
Amarin Corporation plc (ADR) (AMRN) & More: Who’s Being Tested? (InsiderMonkey)
A study published in The New England Journal of Medicine testing omega-3 fatty acids — commonly found in fish oil — in patients with risk factors for cardiovascular disease came up with a pretty wishy-washy conclusion. The take-home message from the study: Fish oil given at the dose used in the trial didn’t reduce cardiovascular mortality and morbidity in the population tested. …Amarin Corporation plc (ADR) (NASDAQ:AMRN) is testing Vascepa in a heart outcomes trial. The results are likely to dictate whether the drug stays on the market or, at the very least, how well it sells. Changing laboratory tests is nice, but outcomes are what doctors and patients really care about.